Preclinical studies have shown a strong therapeutic effect of different NOTCH1 inhibitors, such as γ-Secretase (GS) and ADAM (Disintegrin Metalloproteases) inhibitors, monoclonal antibody, and molecules that block the activity of the NOTCH1 transcription factor complex, in both T-ALL cell lines and primary samples [68]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.